These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32268374)

  • 41. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis.
    Flacco ME; Acuti Martellucci C; Bravi F; Parruti G; Cappadona R; Mascitelli A; Manfredini R; Mantovani LG; Manzoli L
    Heart; 2020 Oct; 106(19):1519-1524. PubMed ID: 32611676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
    De Cauwer H
    Intern Emerg Med; 2020 Nov; 15(8):1581-1582. PubMed ID: 32564289
    [No Abstract]   [Full Text] [Related]  

  • 43. Managing hypertension during the COVID-19 pandemic.
    Nadar SK; Tayebjee MH; Stowasser M; Byrd JB
    J Hum Hypertens; 2020 Jun; 34(6):415-417. PubMed ID: 32409727
    [No Abstract]   [Full Text] [Related]  

  • 44. Surviving the first COVID-19 wave and learning lessons for the second.
    de Brouwer R; van Veldhuisen DJ; de Boer RA
    Eur J Heart Fail; 2020 Jun; 22(6):975-977. PubMed ID: 32564415
    [No Abstract]   [Full Text] [Related]  

  • 45. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Trifirò G; Crisafulli S; Andò G; Racagni G; Drago F;
    Drug Saf; 2020 Jun; 43(6):507-509. PubMed ID: 32303915
    [No Abstract]   [Full Text] [Related]  

  • 46. COVID-19 and cardiovascular comorbidities: An update.
    Teixeira R; Santos M; Gil V
    Rev Port Cardiol (Engl Ed); 2020 Aug; 39(8):417-419. PubMed ID: 32718858
    [No Abstract]   [Full Text] [Related]  

  • 47. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply.
    Albini A; Noonan DM; Pelosi G; Di Guardo G; Lombardo M
    Intern Emerg Med; 2020 Nov; 15(8):1583-1584. PubMed ID: 32666177
    [No Abstract]   [Full Text] [Related]  

  • 48. COVID-19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?
    Thomson G
    Int J Clin Pract; 2020 Jul; 74(7):e13503. PubMed ID: 32187421
    [No Abstract]   [Full Text] [Related]  

  • 49. Reply to the Comment by Dr. Cure on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade".
    Perico L; Benigni A; Remuzzi G
    Nephron; 2020; 144(5):253-254. PubMed ID: 32335551
    [No Abstract]   [Full Text] [Related]  

  • 50. COVID-19 pandemic and economic cost; impact on forcibly displaced people.
    Kabir M; Afzal MS; Khan A; Ahmed H
    Travel Med Infect Dis; 2020; 35():101661. PubMed ID: 32272198
    [No Abstract]   [Full Text] [Related]  

  • 51. ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients.
    Daoud A; Ali H; Rao V; Rohan V; Soliman K
    Ren Fail; 2021 Dec; 43(1):1463-1464. PubMed ID: 34704916
    [No Abstract]   [Full Text] [Related]  

  • 52. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
    Volpe M; Patrono C
    Eur Heart J; 2021 Mar; 42(11):1061-1062. PubMed ID: 33659979
    [No Abstract]   [Full Text] [Related]  

  • 53. Response to "How Important Is the Assessment of Soluble ACE-2 in COVID-19?".
    Rieder M; Bode C; Duerschmied D; Lother A
    Am J Hypertens; 2021 Apr; 34(3):298. PubMed ID: 33201224
    [No Abstract]   [Full Text] [Related]  

  • 54. A practical treatment for COVID-19 and the next pandemic.
    Bhattacharya J; Booy R; Casadevall A; Dela Cruz C; Fedson DS; Garcia JGN; Grohmann G; Hung IFN; Jacobson JR; Jennings LC; Kobzik L; Leligdowicz A; Liao JK; Martin JH; Musher DM; Serhan CN; Tashiro M
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00988. PubMed ID: 35837790
    [No Abstract]   [Full Text] [Related]  

  • 55. Is there a difference in the effect between the ACEI and ARB on COVID-19?
    Chen J; Mei K; Deng C
    Clin Cardiol; 2021 Jan; 44(1):5-6. PubMed ID: 33205837
    [No Abstract]   [Full Text] [Related]  

  • 56. Rethinking travel in a post-pandemic world.
    Glausiusz J
    Nature; 2021 Jan; 589(7840):155-157. PubMed ID: 33402718
    [No Abstract]   [Full Text] [Related]  

  • 57. ARNI, LBBB, COVID-19 and various other topics.
    Erol Ç
    Anatol J Cardiol; 2021 Mar; 25(3):151. PubMed ID: 33690127
    [No Abstract]   [Full Text] [Related]  

  • 58. Pandemics and Protections: How to Keep It All Together in 2020.
    Rebillard G
    Narrat Inq Bioeth; 2021; 11(1):E13-E15. PubMed ID: 34334450
    [No Abstract]   [Full Text] [Related]  

  • 59. Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
    van Kempen ZL; Killestein J; Hartung HP
    Mult Scler; 2021 Dec; 27(14):2123-2125. PubMed ID: 34783282
    [No Abstract]   [Full Text] [Related]  

  • 60. [Controversy regarding ACE inhibitors / ARBs in COVID-19].
    Soria Arcos F; Romero Puche A; Vicente Vera T
    Rev Esp Cardiol; 2020 Jun; 73(6):516. PubMed ID: 32292227
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.